Claims for Patent: 8,128,929

✉ Email this page to a colleague

Summary for Patent: 8,128,929

Title:	Antibodies against PDGFRa
Abstract:	The invention provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFRα and methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.
Inventor(s):	Nick LOIZOS, Jim Huber
Assignee:	University of Washington , Philadelphia Health and Education Corp , ImClone LLC
Application Number:	US11/917,890

Details for Patent 8,128,929

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	October 19, 2016	8,128,929	2026-06-19
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	July 10, 2017	8,128,929	2026-06-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,128,929

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006138729	⤷ Get Started Free
United States of America	8574578	⤷ Get Started Free
United States of America	8425911	⤷ Get Started Free
United States of America	2012034244	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.